Document:

EX-10.2

Amendment No. 3

To

Change in Control Agreement

THIS AMENDMENT NO.3 (“Amendment No.3”) to the Change in Control Agreement referred to herein
below by and between eFunds Corporation, a Delaware corporation (the “Company”) and Steven F.
Coleman (the “Executive”), recites and provides as follows:

RECITALS

WHEREAS, Executive entered into a Change in Control Agreement with the Company on May 12, 2000
(such agreement referred to herein as the “Change in Control Agreement”); and

WHEREAS, pursuant to this Amendment No. 3 the parties wish to amend the Change in Control
Agreement as provided below;

NOW, THEREFORE, in consideration of the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the
Company and the Executive agree as follows:

AGREEMENT

1. Amendments. (a) Section V.A.2. of the Change in Control Agreement is hereby amended to
read as follows:

2. “the Company shall pay to the Executive a lump sum cash payment equal to: (i) $9,000.00 dollars
on the date that is 6 months after the Date of Termination; (ii) payments of $1,500.00 dollars per
month for 12 months thereafter; and (iii) payments of $2,167.00 dollars per month for 18 months
thereafter, in lieu of any continuing benefits under any welfare benefit plans, practices, policies
and programs (including, without limitation, medical, prescription, dental, disability, employee
life, group life, accidental death and travel accident insurance plans and programs);
provided, however, that if the Executive becomes re-employed with another employer
and is eligible to receive medical and dental benefits under another employer provided plan, the
payments set forth in (ii) and (iii) herein shall thereafter cease. The Executive shall notify the
Company if and when he or she becomes re-employed with another employer and is eligible to receive
medical and dental benefits under another employer provided plan.”

(b) Section V.A.4. of the Change in Control Agreement is hereby deleted; and

(c) Section XI.J. is hereby added to the Change in Control Agreement and shall read as follows:
“All payments and benefits under this Agreement shall be made and provided in a manner that is
intended to comply with Section 409A of the Code, to the extent applicable, which does not reduce
the benefits to be received hereunder. Notwithstanding any provision in this Agreement to the
contrary, any payment required to be made to the Executive, pursuant to Sections V.A.1.(b) and (c)
and Section VIII., as a result of the termination of the Executive’s employment shall be delayed
for 6 months after the Date of Termination, the period of time necessary to meet the requirements
of Section 409A(a)(2)(B)(i) of the Code. On the date that is 6 months after the Date of
Termination, there shall be paid to the Executive, in a single cash lump sum, an amount equal to
the aggregate amount of all payments delayed pursuant to the preceding sentence without any
adjustment for delay in payment.”

2. Definitions. Capitalized terms used and not defined in this Amendment No. 3 shall have
the meanings ascribed to such terms in the Change in Control Agreement.

3. Continuing Effect of Change in Control Agreement. Except as expressly provided herein to
the contrary, the Change in Control Agreement shall remain unaffected and continue in full force
and effect after the date hereof.

4. References to Change in Control Agreement. From and after the execution and delivery of
this Amendment No. 3, all references to the Change in Control Agreement in the Change in Control
Agreement or any other document executed or delivered in connection therewith shall be deemed a
reference to the Change in Control Agreement as amended hereby, unless the context expressly
requires otherwise.

5. Counterparts. This Amendment No. 3 may be executed by one or more of the parties to this
Amendment No. 3 on any number of separate counterparts (including counterparts delivered by
telecopy), and all of said counterparts taken together shall be deemed to constitute one and the
same instrument. Any such counterpart delivered by telecopy shall be effective as an original for
all purposes.

6. Governing Law. This Amendment No .3 shall be governed by and construed in accordance
with the laws of the State of Delaware, without reference to principles of conflict of laws.

EFUNDS CORPORATION

	 	 	 
	By:

	 	/s/ Paul F. Walsh     
	
 
	 	 
	
 
	 	Name: Paul F. Walsh

	 	 	Title: Chairman and CEO

EXECUTIVE

	 	 	 
	By:

	 	/s/ Steven F. Coleman
	
 
	 	 
	
 
	 	Name: Steven F. Coleman

	 	 	Title: EVP, Secretary and General CounselEX-10.3

Amendment No. 1

To

Change in Control Agreement

THIS AMENDMENT NO.1 (“Amendment No.1”) to the Change in Control Agreement referred to herein
below by and between eFunds Corporation, a Delaware corporation (the “Company”) and George W.
Gresham (the “Executive”), recites and provides as follows:

RECITALS

WHEREAS, Executive entered into a Change in Control Agreement with the Company on April 1,
2005 (such agreement referred to herein as the “Change in Control Agreement”); and

WHEREAS, pursuant to this Amendment No. 1 the parties wish to amend the Change in Control
Agreement as provided below;

NOW, THEREFORE, in consideration of the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the
Company and the Executive agree as follows:

AGREEMENT

1. Amendments. (a) Section V.A.2. of the Change in Control Agreement is hereby amended to
read as follows:

2. “the Company shall pay to the Executive a lump sum cash payment equal to: (i) $9,000.00 dollars
on the date that is 6 months after the Date of Termination; (ii) payments of $1,500.00 dollars per
month for 12 months thereafter; and (iii) payments of $2,167.00 dollars per month for 18 months
thereafter, in lieu of any continuing benefits under any welfare benefit plans, practices, policies
and programs (including, without limitation, medical, prescription, dental, disability, employee
life, group life, accidental death and travel accident insurance plans and programs);
provided, however, that if the Executive becomes re-employed with another employer
and is eligible to receive medical and dental benefits under another employer provided plan, the
payments set forth in (ii) and (iii) herein shall thereafter cease. The Executive shall notify the
Company if and when he or she becomes re-employed with another employer and is eligible to receive
medical and dental benefits under another employer provided plan.”

(b) Section V.A.4. of the Change in Control Agreement is hereby deleted; and

(c) Section XI.J. is hereby added to the Change in Control Agreement and shall read as follows:
“All payments and benefits under this Agreement shall be made and provided in a manner that is
intended to comply with Section 409A of the Code, to the extent applicable, which does not reduce
the benefits to be received hereunder. Notwithstanding any provision in this Agreement to the
contrary, any payment required to be made to the Executive, pursuant to Sections V.A.1.(b) and (c)
and Section VIII., as a result of the termination of the Executive’s employment shall be delayed
for 6 months after the Date of Termination, the period of time necessary to meet the requirements
of Section 409A(a)(2)(B)(i) of the Code. On the date that is 6 months after the Date of
Termination, there shall be paid to the Executive, in a single cash lump sum, an amount equal to
the aggregate amount of all payments delayed pursuant to the preceding sentence without any
adjustment for delay in payment.”

2. Definitions. Capitalized terms used and not defined in this Amendment No. 1 shall have
the meanings ascribed to such terms in the Change in Control Agreement.

3. Continuing Effect of Change in Control Agreement. Except as expressly provided herein to
the contrary, the Change in Control Agreement shall remain unaffected and continue in full force
and effect after the date hereof.

4. References to Change in Control Agreement. From and after the execution and delivery of
this Amendment No. 1, all references to the Change in Control Agreement in the Change in Control
Agreement or any other document executed or delivered in connection therewith shall be deemed a
reference to the Change in Control Agreement as amended hereby, unless the context expressly
requires otherwise.

5. Counterparts. This Amendment No. 1 may be executed by one or more of the parties to this
Amendment No. 1 on any number of separate counterparts (including counterparts delivered by
telecopy), and all of said counterparts taken together shall be deemed to constitute one and the
same instrument. Any such counterpart delivered by telecopy shall be effective as an original for
all purposes.

6. Governing Law. This Amendment No .1 shall be governed by and construed in accordance
with the laws of the State of Delaware, without reference to principles of conflict of laws.

EFUNDS CORPORATION

By: /s/ Paul F. Walsh     

Name: Paul F. Walsh

Title: Chairman and CEO

EXECUTIVE

By: /s/ George W. Gresham

Name: George W. Gresham

Title: Chief Financial OfficerEX-10.4

Exhibit 10.4

Laura De Cespedes, Nelson G. Eng, Shailesh M. Kotwal, Kay J. Nichols and Clyde L. Thomas have
entered into amendments that are substantially identical in all respects to the amendment executed
between the Company and George W. Gresham filed as Exhibit 10.3 to this Current Report.EX-10.1

NON-COMPETITION AGREEMENT (this “Agreement”), dated as of August 14,
2007, between Noven Pharmaceuticals, Inc., a Delaware corporation (the
“Parent”), and Phillip Satow, an individual (the “Seller Affiliate”).

WHEREAS the Seller Affiliate is a member of Satow Associates, LLC, a New York limited
liability company (“Satow Associates”) that is a member of JDS Pharmaceuticals, LLC, a Delaware
limited liability company (the “Company”), and is an affiliate and indirect owner of the Company;

WHEREAS pursuant to, and subject to the terms and conditions of, the Agreement and Plan of
Merger, dated as of July 9, 2007, by and among the Parent, Noven Acquisition, LLC, a Delaware
limited liability company and wholly-owned subsidiary of the Parent (the “Sub”), the Company and
Satow Associates, in its capacity as Member Representative (the “Merger Agreement”), the Sub shall
be merged with and into the Company and the Company shall continue as the surviving entity in the
Merger (as defined in the Merger Agreement) and will become a subsidiary of the Parent;

WHEREAS pursuant to, and subject to the terms and conditions of the Merger Agreement, the
Seller Affiliate shall receive the consideration provided for the Merger Agreement in exchange for
the Units, Phantom Units and Hurdle Units (each as defined in the Merger Agreement) held directly
or indirectly, through Satow Associates, by the Seller Affiliate.

WHEREAS following the Merger, the Parent intends to continue to conduct and operate the
business of the Company;

WHEREAS each of the Parent and the Seller Affiliate acknowledges and agrees that a material
aspect of the Parent’s decision to enter into the Merger Agreement is the acquisition of the
Company’s goodwill for the purpose of the Parent’s and the Company’s continuing to carry on the
Company’s business or a business similar to the Company’s business;

WHEREAS as an inducement to the Parent to consummate the Merger and in consideration of the
benefits set forth herein, the Seller Affiliate is entering into this Agreement;

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set
forth, the parties hereto agree as follows:

SECTION 1. Effectiveness. This Agreement shall be effective as of the Effective Date
(as defined in the Merger Agreement), and shall be null and void ab initio and of no further force
and effect if the Merger Agreement is terminated in accordance with its terms prior to the
consummation of the Merger.

SECTION 2. Non-competition. The Seller Affiliate covenants and agrees that, during
the Restricted Period (as defined in Section 5), without the prior written consent of the Parent
and except as a result of his status, or performance of his duties, as a director of those
companies (and any successors thereto) for whom he is acting as a director on the date hereof and
which are set forth on Schedule A to this Agreement, he shall not, directly or indirectly, either
on his own behalf or on the behalf of any other entity (a) become “Associated With” any “Competing
Business” (each as defined below), (b) solicit, sell, call upon or induce others to solicit, sell
or call upon, directly or indirectly, any distributor or other purchaser of the Parent’s or the
Company’s products within the twelve months preceding any such action by the Seller Affiliate
(collectively, “Purchasers”), or any prospective Purchasers, for the purpose of inducing any such
Purchaser to purchase, a Competitive Product (as defined below), (c) except in connection with the
performance of his services for the Parent or the Company, solicit or attempt to solicit any person
(other than April Thoren) who is then employed or engaged to perform services by the Parent or the
Company to become employed by or enter into contractual relations with any individual or entity
other than the Parent or the Company, or in any manner induce, seek to induce, entice or endeavor
to entice any such person (other than April Thoren) to leave his or her employment or engagement
with the Parent or the Company or (d) except in the performance of his services with the Parent or
the Company, induce any supplier, vendor, consultant or independent contractor of the Parent or the
Company to terminate or negatively alter his, her or its relationship with the Parent or the
Company.

SECTION 3. Payment. Effective as of the Closing (as defined in the Merger Agreement),
the Parent shall grant the Seller Affiliate a number of stock appreciation rights with respect to
Parent common stock with an aggregate Black-Scholes value (as determined based on the assumptions
used by the Parent for financial accounting purposes) equal to $265,200 (the “SARs). All such SARs
shall be fully vested as of the Closing, shall be exercisable for seven years following the Closing
and shall be settled in Parent common stock. Each of the Parent and the Seller Affiliate
acknowledge that (a) following the Closing, the Seller Affiliate shall serve as a consultant to the
Company, which shall be a subsidiary of the Parent following the Closing, pursuant to a Consulting
Agreement dated on or about the date hereof between the Company and the Consultant and (b) the
terms of the SARs shall be set forth in an award agreement substantially in the form of award
agreement generally provided under the Parent’s 1999 Long-Term Incentive Plan (modified as
appropriate to reflect the terms of this Section 3).

SECTION 4. Certain Definitions. For purposes of this Agreement, the following terms
shall have the following meanings:

(a) “Associated With” means serving as an owner, officer, employee, independent contractor,
agent or a holder of 5% or more of any class of equity securities of, or as a director, trustee,
member, consultant or partner of, any person, corporation (for profit or not for profit) or other
entity engaged in a Competing Business; provided, however, that the Seller
Affiliate shall not be deemed to be “Associated With” any Competing Business for which he acts
solely as a consultant or employee if his services do not relate to a Competitive Product.

(b) “Competing Business” means any business that is engaged in the acquisition, manufacture,
development or sale of Competitive Products.

(c) “Competitive Products” means any pharmaceutical or biotechnology products which compete in
the same markets (which, for purposes of this Agreement, shall mean products having the same FDA
approved labeled indications or products commonly prescribed for indications for which the
Company’s products are commonly prescribed) as any product of the Company which is sold or is under
active development by the Company during the Restricted Period.

SECTION 5. Non-compete/Non-solicit Period. The covenant not to compete and the
nonsolicitation covenant set forth in Section 2 shall restrict the Seller Affiliate from the
Effective Date until three (3) years after the Effective Date (such period, the “Restricted
Period”).

SECTION 6. Reasonableness of Provisions; Severability; Compliance. Each of the Seller
Affiliate and the Parent acknowledges and agrees that the covenants and agreements contained in
this Agreement have been negotiated in good faith by the parties hereto, and are reasonable and are
not more restrictive or broader than necessary to protect the interests of the parties hereto, and
would not achieve their intended purpose if they were on different terms or for periods of time
shorter than the periods of time provided herein or applied in more restrictive geographical areas
than are provided herein. Each party further acknowledges that the Parent would not enter into the
Merger Agreement and the transactions contemplated thereby in the absence of the covenants and
agreements contained in this Agreement and such covenants and agreements are essential to protect
the value of the Parent and the Company. It is expressly understood and agreed that although
Seller Affiliate and the Parent consider the restrictions contained in this Agreement to be
reasonable, if a final judicial determination is made by a court of competent jurisdiction that the
time or territory restriction in this Agreement or other restriction contained in this Agreement is
an unenforceable restriction against the Seller Affiliate, such provision shall not be rendered
void but shall be deemed amended to apply to such maximum time and territory, if applicable, or
otherwise to such maximum extent as such court may judicially determine or indicate to be
enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction
contained in this Agreement, and such restriction cannot be amended so as to make it enforceable,
such finding shall not affect the enforceability of any of the other restrictions contained herein.
In the event that any one or more of the other provisions of this Agreement shall be or become
invalid, illegal or unenforceable in any respect, the validity, legality and nonenforceability of
the remaining provisions of this Agreement shall not be affected thereby. The Seller Affiliate
agrees to comply with the covenants contained in this Agreement in accordance with their terms, and
the Seller Affiliate shall not, and hereby agrees to waive and release any right or claim to,
challenge the reasonableness, validity or enforceability of any of the covenants contained in this
Agreement.

SECTION 7. Jurisdiction. The parties hereto intend to and hereby confer jurisdiction
to enforce the covenants contained in this Agreement upon the courts of any state within the
geographical scope of such covenants. In the event that the courts of any one or more of such
states shall hold such covenants wholly unenforceable by reason of the breadth of such covenants or
otherwise, it is the intention of the parties hereto that such determination not bar or in any way
affect the Parent’s right to the relief provided above in the courts of any other states within the
geographical scope of such covenants as to breaches of such covenants in such other respective
jurisdictions, the above covenants as they relate to each state being, for this purpose, severable
into diverse and independent covenants.

SECTION 8. Equitable Relief. The Seller Affiliate acknowledges and agrees that the
Parent’s remedies at law for breach of any of the provisions of this Agreement would be inadequate
and, in recognition of this fact, the Seller Affiliate agrees that, in the event of such breach, in
addition to any remedies at law it may have, the Parent shall be entitled to obtain equitable
relief in the form of specific performance, a temporary restraining order, a temporary or permanent
injunction or any other equitable remedy that may be available. The Seller Affiliate further
acknowledges that should the Seller Affiliate violate any of the provisions of this Agreement, it
will be difficult to determine the amount of damages resulting to the Parent or its affiliates and
that in addition to any other remedies the Parent may have, the Parent shall be entitled to
temporary and permanent injunctive relief.

SECTION 9. Notification of Subsequent Employer. The Seller Affiliate hereby agrees
that prior to accepting employment with any other person or entity at any time during the
Restricted Period, the Seller Affiliate will provide such prospective employer with written notice
of the provisions of this Agreement, with a copy of such notice delivered simultaneously to the
Parent.

SECTION 10. Not An Employment Agreement. This Agreement is not, and nothing in this
Agreement shall be construed as, an agreement to provide employment to the Seller Affiliate.

SECTION 11. Notices. All notices, requests, consents and other communications
required or permitted to be given hereunder shall be in writing and shall be deemed to have been
duly given if delivered personally, sent by overnight courier or mailed first class, postage
prepaid, by registered or certified mail (notices mailed shall be deemed to have been given on the
date mailed), as follows (or to such other address as either party shall designate by notice in
writing to the other in accordance herewith):

If to the Parent, to:

Noven Pharmaceuticals, Inc.

11960 SW 114th Street

Miami, FL 33186

Attention: General Counsel

Facsimile: (305) 232-1836

With a copy to:

Cravath, Swaine & Moore LLP

825 8th Avenue

New York, NY 10019

Attention: Richard Hall

Facsimile: (212) 474-3700

If to the Seller Affiliate, to:

Phillip M. Satow

158 Mercer Street

New York, NY 10012

With a copy to:

Latham & Watkins LLP

885 Third Avenue

New York, NY 10022

Attention: Bradd Williamson

Facsimile: (212) 751-4864

SECTION 12. General.

(a) Governing Law; Waiver of Jury Trial. This Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of New York applicable to
agreements made and to be performed entirely in New York. EACH PARTY ACKNOWLEDGES AND AGREES THAT
ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY
MAY HAVE TO A TRIAL BY JURY IN RESPECT OF OR ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF
OR RELATING TO THIS AGREEMENT, OR THE BREACH, TERMINATION OR VALIDITY OF THIS AGREEMENT. Each
party certifies and acknowledges that (i) no representative, agent or attorney of any other party
has represented, expressly or otherwise, that such other party would not, in the event of
litigation, seek to enforce the foregoing waiver, (ii) each such party understands and has
considered the implications of this waiver, (iii) each such party makes this waiver voluntarily and
(iv) each such party has been induced to enter into this agreement by, among other things, the
mutual waivers and certifications in this Section 12(a). With respect to any such litigation, the
out-of-pocket fees and expenses (including reasonable attorneys’ fees) of the prevailing party
shall be borne by the nonprevailing party upon final resolution of all claims related to such
litigation by a court of competent jurisdiction.

(b) Section Headings. The section headings contained herein are for reference
purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

(c) Advance Determination of Permitted/Prohibited Conduct. The Seller Affiliate may
request an advance written determination from the Parent as to whether his taking a proposed action
or his involvement in a proposed endeavor would, in the Parent’s opinion, constitute a material
breach of the provisions of this Agreement. In that event, and provided that the Seller Affiliate
discloses in writing all material facts about the proposed action or endeavor, the advance written
determination shall be made as soon as practicable in the circumstances, without any unreasonable
delay or withholding; provided, that if circumstances materially change after the advance
determination is made (e.g., the extent of the Seller Affiliate’s involvement with a proposed
endeavor changes after the Seller Affiliate undertakes it), the Parent may reconsider, revise
and/or reverse the determination upon thirty days advance written notice to the Seller Affiliate.

(d) Assignability. This Agreement, and the Seller Affiliate’s rights and obligations
hereunder, may not be assigned by the Seller Affiliate.

(e) Amendments. This Agreement may be amended, modified, superseded, canceled,
renewed or extended and the terms or covenants hereof may be waived, only by a written instrument
executed by both of the parties hereto, or in the case of a waiver, by the party waiving
compliance. The failure of the Parent at any time or times to require performance of any provision
hereof shall in no manner affect the right at a later time to enforce the same. No waiver by the
Parent of the breach of any term or covenant contained in this Agreement, whether by conduct or
otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such breach, or a waiver of the breach of any other term or covenant
contained in this Agreement.

(f) Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original and enforceable against the parties actually executing such
counterpart, and all of which together shall constitute one and the same instrument.

(g) Further Assurances. The Seller Affiliate shall, from time to time, upon the
request of the Parent, duly execute, acknowledge and deliver or cause to be duly executed,
acknowledged and delivered, all such further instruments and documents reasonably requested by the
Buyer to further effectuate the intent and purposes of Section 9.

(h) Entire Agreement. This Agreement sets forth the entire agreement and
understanding of the parties relating to the subject matter hereof and supersedes all prior
agreements, arrangements and understandings, written or oral, relating to the subject matter
hereof; provided, however, that this Agreement does not impair, diminish, restrict
or waive any other restrictive covenant of the Seller Affiliate to the Company or the Parent under
any other agreement, policy, plan or program of the Company or the Parent not expressly set forth
herein.

[The remainder of this page is intentionally left blank.]

1

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

NOVEN PHARMACEUTICALS, INC.,

By: /s/ Robert C. Strauss

Name: Robert C. Strauss

Title: President, Chief Executive Officer and Chairman of the Board

Seller Affiliate:

/s/ Phillip Satow

Phillip Satow

COMPANIES FOR WHICH THE SELLER AFFILIATE SERVES AS A DIRECTOR

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]